Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
It’s just another earnings week in the life of pharmaceutical CEOs, with blockbuster expectations running up against cruel reality.
Chinese electric vehicle giant BYD announced revenue of just over $28 billion in the three months ending September.
Royal Caribbean raised its annual profit forecast for the fourth time this year. Driving the optimism is a private island in the Bahamas.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
MLB World Series viewership is way up, thanks in part to Japan-born Los Angeles Dodger Shohei Ohtani. And brands have noticed.
Mercedes-Benz is en route to cut costs after profits in the third quarter more than halved year-over-year due to weaker demand in China.
Boeing is considering a sale of its space unit, among other assets. The news comes as its bottom line grows more tenuous.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
TKO Group will be dropping $3.25 billion to acquire a trio of sports and entertainment properties from Endeavor.
Modifi Biosciences announced that it has been acquired by global pharmaceutical giant Merck, with a $30 million down payment.
Frontier Airlines and Spirit Airlines have renewed their yearslong on-again, off-again merger flirtation. Perhaps this time’s the charm.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.